Drug Database
Back to search

Poland· PL-100306894

Dexilant

A dexlansoprazole product containing dexlansoprazolum, registered in Poland by Takeda Pharma Sp. z o.o.. The same ATC class is registered in 6 of our 19 countries.

ATC A02BC06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDexilantATCA02BC06REGISTER NO.PL-100306894PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dexlansoprazolumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dexlansoprazole is registered in 6 of 19 countries.

Countries holding a registration under ATC A02BC06 (dexlansoprazole), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 4 of them publish a price we can compare per daily dose
Search dexlansoprazole products by name

Dexlansoprazole · ATC A02BC06

6 / 19 countries

  • Belgiumprice
  • Canada
  • Germany
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dexlansoprazole costs, country by country.

Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Dexlansoprazole · price per daily dose (30 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1.25
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Dexlansoprazolum
Manufacturer
Takeda Pharma Sp. z o.o.
Country
Poland (PL)
ATC code
A02BC06
ATC class
Dexlansoprazole
Defined daily dose
30 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991096755
  • gtin
    05909991096762

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

142 interactions on record for dexlansoprazole.

Graded by severity as the source publishes them — 22 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dexlansoprazole against other medicinesHow interaction checks work

Dexlansoprazole · interactions on record

142 records

  • 22 severe
  • 87 moderate
  • 29 minor

Most severe, free to view

  • NelfinavirJ05AE04severe
  • AtazanavirJ05AE08severe
  • RilpivirineJ05AG05severe
  • Sofosbuvir and velpatasvirJ05AP55severe

4 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dexlansoprazole in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dexlansoprazole products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Germany · Dexilant
  • Lithuania · Dexilant

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d653ae28-76ff-4831-9619-5361b5b93af4
GET /v1/drugs/d653ae28-76ff-4831-9619-5361b5b93af4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki o zmodyfikowanym uwalnianiu, twarde",
  "source": "urpl",
  "strength": "60 mg",
  "packaging": "05909991096755 ¦ Rp ¦ 87681\n14 kaps.\n05909991096762 ¦ Rp ¦ 87682\n28 kaps.",
  "substance": "Dexlansoprazolum 22.5 mg",
  "common_name": "Dexlansoprazolum",
  "pl_product_id": "100306894",
  "pozwolenie_nr": "21617",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about dexlansoprazole.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console